Although there have been no recent approvals of oral JAK inhibitors (JAK-i) for atopic dermatitis (AD), some interesting study findings have been published. These shed light on the safety of baricitinib, abrocitinib and upadacitinib with reference to the EMA opinion on JAK-i issued some time ago. In the EU, baricitinib has now been given an extended indication for AD patients aged 2 years and older.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Asthma in adults
When do pneumology specialists come into play?
- Cutaneous lupus erythematosus
From diagnostic workup to successful treatment
- Guideline update
Dietary recommendations for Crohn’s disease and colitis
- Circadian rhythm during Ramadan
Disturbed sleep patterns lead to metabolic stress
- Case Report
Breast cancer metastases in the bladder
- Findings from the ALS Symposium 2024 in Montreal
Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)
- Efficacy, mechanism of action and clinical effects
Garlic and high blood pressure
- Moderate to severe chronic hand eczema